Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers

Abstract The main goal of prostate cancer tissue biomarkers is to improve diagnostic and prognostic accuracy. A particularly important question is whether the cancer needs immediate treatment or if treatment can be deferred. It is highly unlikely that a single biomarker that provides comprehensive prognostic information about a newly diagnosed prostate cancer will be forthcoming. Despite extensive research efforts, very few biomarkers of prostate cancer have been successfully implemented into clinical practice today. This can be partly explained by a lack of standardised methods for performance and interpretation of immunohistochemistry, but also by poor study design with insufficient biomaterial or inappropriate statistical analysis. Also appropriate cohorts to test prostate cancer biomarkers do not exist. It must be kept in mind that unsuccessful integration of new biomarkers in nomograms can also be explained by the good performance of the clinical and pathological base model with serum PSA as the only independent biomarker. A new biomarker must be powerful enough to improve this prediction model and not merely replace. Material and methods. In this report, we focus on diagnostic and prognostic cellular biomarkers in prostate cancer, recent advances and future aspects by reviewing currently available literature. Results. Similar to other malignancies, the proliferation marker Ki-67 seems to be a prognostic tissue biomarker and a strong candidate for integration in prediction models. Circulating tumour cells are promising markers of response to treatments in patients with metastatic disease. Conclusion. Important technical advances together with histological techniques of antibody or probes conjugated with different fluorophores will certainly improve standardisation and make immunohistochemical biomarker research more reliable and precise in the future. Cellular biomarker studies are also expected to change in the future towards a complexed individualised profiling of human tumours with integrative analysis using different technologies, genome-wide scanning and expression profiling.

[1]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[2]  Jiaoti Huang,et al.  Identification of a Cell of Origin for Human Prostate Cancer , 2010, Science.

[3]  I. Leav,et al.  Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. , 2010, The American journal of pathology.

[4]  Howard H. Wu,et al.  Comparison of 34βE12 and P63 in 100 Consecutive Prostate Carcinoma Diagnosed by Needle Biopsies , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[5]  N. Clarke,et al.  Use of classical and novel biomarkers as prognostic risk factors for localised prostate cancer: a systematic review. , 2009, Health technology assessment.

[6]  Stig Nordling,et al.  Relative concentrations of hK2/PSA mRNA in benign and malignant prostatic tissue , 2005, The Prostate.

[7]  H. Lilja,et al.  Three predominant proteins secreted by the human prostate gland , 1988, The Prostate.

[8]  J. Epstein,et al.  Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: implications for patient care. , 2006, The Journal of urology.

[9]  Ali Amin Al Olama,et al.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008, Nature Genetics.

[10]  J. Clements,et al.  Tissue-specific Expression Patterns and Fine Mapping of the Human Kallikrein (KLK) Locus on Proximal 19q13.4* , 2000, The Journal of Biological Chemistry.

[11]  Pier Paolo Pandolfi,et al.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate , 2009, Nature Genetics.

[12]  M. Wroclawski,et al.  Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. , 2010, The Journal of urology.

[13]  J. Epstein,et al.  Partial Atrophy on Prostate Needle Biopsy Cores: A Morphologic and Immunohistochemical Study , 2008, The American journal of surgical pathology.

[14]  T. DeWeese,et al.  Loss-of-function of Nkx3.1 promotes increased oxidative damage in prostate carcinogenesis. , 2005, Cancer research.

[15]  U. Stenman,et al.  Biochemistry and Clinical Role of Trypsinogens and Pancreatic Secretory Trypsin Inhibitor , 2006, Critical reviews in clinical laboratory sciences.

[16]  James D. Brooks,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008 .

[17]  T. Soussi,et al.  Cancer and the heat shock response. , 1994, European journal of cancer.

[18]  D. Bostwick,et al.  Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. , 1999, Journal of the National Cancer Institute.

[19]  J. Brooks.  Multiple newly identified loci associated with prostate cancer susceptibility , 2008 .

[20]  J. Brooks,et al.  Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[22]  J. Epstein,et al.  Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer , 2003, The American journal of surgical pathology.

[23]  Oscar Lin,et al.  Fluorescence In situ Hybridization Analysis of Circulating Tumor Cells in Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[24]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[25]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[26]  D. Tindall,et al.  Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. , 1999, Urology.

[27]  G G Klee,et al.  Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. , 1997, Urology.

[28]  Shahrokh F. Shariat,et al.  Inventory of prostate cancer predictive tools , 2008, Current opinion in urology.

[29]  P. Ekman,et al.  Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer   , 2008, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[30]  D. Bostwick,et al.  Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma , 1998, Cancer.

[31]  J Cuzick,et al.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.

[32]  M. Bollen,et al.  The gene encoding the prostatic tumor suppressor PSP94 is a target for repression by the Polycomb group protein EZH2 , 2007, Oncogene.

[33]  Ximing J. Yang,et al.  Expression analysis of putative stem cell markers in human benign and malignant prostate , 2011, The Prostate.

[34]  Todd M Morgan,et al.  Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. , 2009, Current cancer drug targets.

[35]  S. Westerheide,et al.  Heat Shock Response Modulators as Therapeutic Tools for Diseases of Protein Conformation* , 2005, Journal of Biological Chemistry.

[36]  J. Epstein,et al.  False Positive Labeling of Prostate Cancer With High Molecular Weight Cytokeratin: p63 a More Specific Immunomarker for Basal Cells , 2008, The American journal of surgical pathology.

[37]  R. Dhir.  Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases , 2009 .

[38]  Hafiz Ahmed.  Promoter Methylation in Prostate Cancer and its Application for the Early Detection of Prostate Cancer Using Serum and Urine Samples , 2010, Biomarkers in cancer.

[39]  M. Loda,et al.  Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. , 1999, Cancer research.

[40]  J. Epstein,et al.  Aberrant Diffuse Expression of p63 in Adenocarcinoma of the Prostate on Needle Biopsy and Radical Prostatectomy: Report of 21 Cases , 2008, The American journal of surgical pathology.

[41]  J. Cuzick,et al.  p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer , 2009, BJU international.

[42]  Magnus Hellström,et al.  Proteomic analysis of protein expression in prostate cancer. , 2005, Analytical and quantitative cytology and histology.

[43]  J. Epstein,et al.  How Often Does Alpha-Methylacyl-CoA-Racemase Contribute to Resolving an Atypical Diagnosis on Prostate Needle Biopsy Beyond That Provided by Basal Cell Markers? , 2004, The American journal of surgical pathology.

[44]  R Garside,et al.  The harmful health effects of recreational ecstasy: a systematic review of observational evidence. , 2009, Health technology assessment.

[45]  Thomas Wheeler,et al.  High Level of Androgen Receptor Is Associated With Aggressive Clinicopathologic Features and Decreased Biochemical Recurrence-free Survival in Prostate: Cancer Patients Treated With Radical Prostatectomy , 2004, The American journal of surgical pathology.

[46]  R. Lothe,et al.  Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas , 2006, Molecular Cancer.

[47]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[48]  N. Zaffaroni,et al.  Emerging role of microRNAs in prostate cancer: implications for personalized medicine. , 2010, Discovery medicine.

[49]  Matthias D Hofer,et al.  Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.

[50]  F. Hamdy,et al.  High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. , 2010, Cancer research.

[51]  J. McCubrey,et al.  Phosphatidylinositol 3′-Kinase Activation Leads to Multidrug Resistance Protein-1 Expression and Subsequent Chemoresistance in Advanced Prostate Cancer Cells , 2004, Cancer Research.

[52]  U. Stenman,et al.  Increased expression of tumor-associated trypsin inhibitor, TATI, in prostate cancer and in androgen-independent 22Rv1 cells. , 2007, European urology.

[53]  John T. Wei,et al.  The role of SPINK1 in ETS rearrangement-negative prostate cancers. , 2008, Cancer cell.

[54]  K. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate Cancer , 2008, Clinical Cancer Research.

[55]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[56]  Michael W Kattan,et al.  Judging new markers by their ability to improve predictive accuracy. , 2003, Journal of the National Cancer Institute.

[57]  G. Sauter,et al.  Predictive value of prostate-specific antigen expression in prostate cancer: a tissue microarray study. , 2009, Urology.

[58]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[59]  J. Cuzick,et al.  Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study , 2009, British Journal of Cancer.

[60]  M. Rubin,et al.  Basal Cell Cocktail (34&bgr;E12 + p63) Improves the Detection of Prostate Basal Cells , 2003, The American journal of surgical pathology.

[61]  M. Gleave,et al.  Loss of PTEN is associated with progression to androgen independence , 2006, The Prostate.

[62]  H. Scher,et al.  Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer , 2007, Clinical Cancer Research.

[63]  D. Ghosh,et al.  A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. , 2007, Cancer research.

[64]  P. Donnan,et al.  A randomised controlled trial of the use of aciclovir and/or prednisolone for the early treatment of Bell's palsy: the BELLS study. , 2009, Health technology assessment.

[65]  Tapio Visakorpi,et al.  Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.

[66]  Jaya M Satagopan,et al.  TMPRSS2–ERG gene fusion is associated with low Gleason scores and not with high-grade morphological features , 2010, Modern Pathology.

[67]  W. Gerald,et al.  Association of Cysteine-Rich Secretory Protein 3 and β-Microseminoprotein with Outcome after Radical Prostatectomy , 2007, Clinical Cancer Research.

[68]  C. Cordon-Cardo,et al.  Androgen receptor expression is associated with prostate cancer‐specific survival in castrate patients with metastatic disease , 2010, BJU international.

[69]  W. Willett,et al.  Multiple loci identified in a genome-wide association study of prostate cancer , 2008, Nature Genetics.

[70]  W. Isaacs,et al.  &agr;-Methylacyl-CoA Racemase: A Variably Sensitive Immunohistochemical Marker for the Diagnosis of Small Prostate Cancer Foci on Needle Biopsy , 2003, The American journal of surgical pathology.